Pathomechanisms of Cutaneous Lupus Erythematosus
Chapter 23 Pathomechanisms of Cutaneous Lupus Erythematosus Jan P. Dutz Abnormal cutaneous reactivity to sunlight is such a seminal clinical feature of lupus erythematosus (LE) that it is one of…
Antimalarial Medications
Chapter 49 Antimalarial Medications J. Antonio Aviña-Zubieta, John M. Esdaile Introduction Paine first used quinine for the treatment of discoid lupus erythematosus.1 It was not, however, until 1951, when Page…
Autoantigenesis and Antigen-Based Therapy and Vaccination in SLE
Chapter 21 Autoantigenesis and Antigen-Based Therapy and Vaccination in SLE Ram Raj Singh, Julia Pinkhasov, Priti Prasad, Shweta Dubey1, The discovery in the early 1990s that self-antigen–reactive T cells can…
The Pathogenesis of SLE
Chapter 3 The Pathogenesis of SLE Bevra H. Hahn The purpose of this brief chapter is to review how SLE evolves and is sustained. Ideas reflect the author’s opinions, which…
Pregnancy in Women with SLE
Chapter 36 Pregnancy in Women with SLE Megan E.B. Clowse Systemic lupus erythematosus (SLE) primarily affects women of childbearing age; pregnancy is therefore a dilemma frequently encountered in this patient…
Pathogenetic Mechanisms in Lupus Nephritis
Chapter 18 Pathogenetic Mechanisms in Lupus Nephritis Anne Davidson, Celine Berthier, Matthias Kretzler The kidneys maintain homeostasis of water, minerals, electrolytes, and hydrogen ions and eliminate toxic substances produced by…
Critical Issues in Drug Development for SLE
Chapter 54 Critical Issues in Drug Development for SLE Ronald F. van Vollenhoven Introduction The development of new drugs for the treatment of systemic lupus erythematosus (SLE) during the first…
Cardiopulmonary Disease in SLE
Chapter 27 Cardiopulmonary Disease in SLE Guillermo Ruiz-Irastorza, Munther Khamashta Cardiopulmonary Manifestations The heart and the lungs can frequently be affected during the course of systemic lupus erythematosus (SLE), because…
Immunosuppressive Drug Therapy
Chapter 50 Immunosuppressive Drug Therapy W. Joseph McCune, Tania Gonzalez-Rivera Immunosuppressive agents are widely used for serious manifestations of systemic lupus erythematosus (SLE) to minimize irreversible injury and reduce toxicity…
Systemic Glucocorticoid Therapy in SLE
Chapter 48 Systemic Glucocorticoid Therapy in SLE Kyriakos A. Kirou, Dimitrios T. Boumpas Glucocorticoids (GCs), as a result of their powerful antiinflammatory effects, have remained a frontline therapy in rheumatology…
